TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02369926

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Sclerosis Functional Composite
Description: The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Sclerosis Functional Composite
Description: The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Multiple Sclerosis Functional Composite
Description: The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Multiple Sclerosis Functional Composite
Description: The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
Study: NCT04094636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-bed cycling
Description: Patients will daily perform 30 min of supervised in-bed cycling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise booklet
Description: Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
Study: NCT03794323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764122
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT00985790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Intramuscular injection
Study: NCT02623270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilator, V60 (Philips)
Description: The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Bag
Description: Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
Study: NCT04680143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic erythropoietin injection
Description: Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Study: NCT01528774

Intervention type: OTHER
Intervention: Blood Draw
Description: Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.

Intervention type: OTHER
Intervention: Blood Draw
Description: Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.

Intervention type: OTHER
Intervention: Blood Draw
Description: Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.

Intervention type: OTHER
Intervention: Blood Draw
Description: Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.

Intervention type: OTHER
Intervention: Blood Draw
Description: Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
Study: NCT01666314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel
Description: Orteronel tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel Placebo
Description: Orteronel placebo-matching tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel Placebo
Description: Orteronel placebo-matching tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Orteronel Placebo
Description: Orteronel placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone 5 mg
Study: NCT01598220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation therapy
Description: Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: attentional task
Description: The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
Study: NCT00732693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol / Norethisterone
Description: Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol / Progesterone
Description: Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
Study: NCT03281915

Intervention type: PROCEDURE
Intervention: High inguinal Varicocelectomy
Description: Semen parameters after high inguinal varicocelectomy will be collected

Intervention type: PROCEDURE
Intervention: Subinguinal varicocelectomy
Description: Semen parameters after subinguinal Varicocelectomy will be collected
Study: NCT03191201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Study: NCT03896360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food order behavioral intervention plus standard care
Description: Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
Study: NCT00997815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Concentration at 2 units per 0.1 of normal saline dilution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: Using normal saline 2.5 ml injected in control side
Study: NCT03908008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MT10107 (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10107 (Botulinum toxin type A)
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study: NCT03418974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
Study: NCT02002208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Oral CRTH2 antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OC000459
Description: Oral CRTH2 antagonist
Study: NCT00890721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: During the operation, 30cc of SKY0402 are injected into the wound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the hemorrhoidectomy, 30cc Placebo injected into the wound.
Study: NCT02003027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT injection
Study: NCT03443544

Intervention type: PROCEDURE
Intervention: Aggressive debridement
Description: Aggressive debridement of the tissues undergoing fascitis

Intervention type: PROCEDURE
Intervention: Aggressive debridement
Description: Aggressive debridement of the tissues undergoing fascitis

Intervention type: PROCEDURE
Intervention: Aggressive debridement
Description: Aggressive debridement of the tissues undergoing fascitis

Intervention type: PROCEDURE
Intervention: Aggressive debridement
Description: Aggressive debridement of the tissues undergoing fascitis
Study: NCT00326040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma Surgery
Study: NCT00505362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus closure
Description: Reapproximation of the rectus muscles with three-interrupted sutures
Study: NCT01243125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422, 0.2%
Description: 0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline, 0.9%
Description: Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
Study: NCT03281538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
Study: NCT04286503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin
Description: Carrimycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
Description: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: basic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basic treatment
Description: basic treatment
Study: NCT06391515

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample, CRF, thyroid ultrasound
Description: Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample, CRF, thyroid ultrasound
Description: Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
Study: NCT01050842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study: NCT00593645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study: NCT02207179

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: LumaScan Image Guided Surgery
Study: NCT04000711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient oral treatment.
Description: Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient intravenous treatment.
Description: Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
Study: NCT03519607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FertiStrong App
Description: The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
Study: NCT03049800

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
Study: NCT00583804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IST-12
Description: Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IST-12
Description: Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
Study: NCT04102111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67864238
Description: Participants will receive oral tablets of JNJ-67864238 twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral tablets of matching placebo twice daily.
Study: NCT03509597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Physical exercise training consisting of aerobic exercise and strength/resistance training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive remediation program using REHACOP rehabilitation program.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as usual
Description: Standard care for schizophrenia + Leisure and free time activities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Occupational Activities
Description: Engagement in activities aimed to keep patients actively involved in demanding tasks.
Study: NCT03132259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dexmedethomidine
Description: Dexmedethomidine continuous drip 0.5 mcg/kg/hr a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose dexmedethomidine
Description: Dexmedethomidine continuous drip 0.2 mcg/kg/hr
Study: NCT01300520

Intervention type: DEVICE
Group type: OTHER
Intervention: Target Tape
Description: Comparing procedures using Target Tape against procedures not using Target Tape
Study: NCT01451788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin matrix with human derived thrombin (Floseal, Baxter)
Description: Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
Study: NCT02070991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: oral tablet, 10 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT04151498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reengagement and Assessment Mobile Program
Description: Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative Interview
Description: Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview
Description: Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.